BiotechTube
Home/Pipeline/Rosnilimab (ANB030)

Rosnilimab (ANB030)

Rheumatoid Arthritis

Phase 2bActive

Key Facts

Indication
Rheumatoid Arthritis
Phase
Phase 2b
Status
Active
Company
AnaptysBio

About AnaptysBio

AnaptysBio is a San Diego-based clinical-stage biotech focused on developing innovative antibody therapeutics for autoimmune and inflammatory diseases. The company operates a dual-strategy model, advancing a proprietary clinical pipeline while generating revenue from royalties on out-licensed assets like the PD-1 antagonist Jemperli. Its transformational plan to separate into two independent public companies by end of 2026 aims to provide investors with distinct investment theses: high-growth biopharma and stable royalty income.

View full company profile

Therapeutic Areas

Autoimmune DiseasesInflammatory Diseases

Other Rheumatoid Arthritis Drugs

DrugCompanyPhase
Early Detection Test for Rheumatoid ArthritisAge LabsDevelopment
Piclidenoson (CF101)Can Fite BiopharmaPhase II/III
ERNA-201Eterna TherapeuticsPreclinical
Tc99m TilmanoceptNavidea BiopharmaceuticalsPhase 2/3
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)LFBPre-clinical
EYD-001 (Takinib analog)EydisBioPreclinical
LFD-200Lifordi ImmunotherapeuticsPhase 1
MEV-N01MesenbioPre-clinical
CIT-013CitryllPhase 2a
Restem-LRestemPhase 2
ASIT PlatformAhead TherapeuticsPre-clinical
AX-158Artax BiopharmaPhase 2